Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01279057 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis
A Phase 3 study, sponsored by Sandoz.
- Completed
- Registry status
- Phase 3
- Development phase
- 727
- Enrollment target
NCT01279057 is a Phase 3 study that has completed, run by Sandoz. The registered enrollment target is 727 participants.
The verdict
NCT01279057, a Phase 3 study, has completed, sponsored by Sandoz.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 727 participants
- Enrollment target
Study Summary
This study compared the safety and efficacy of a generic fluticasone furoate (Lek Pharmaceuticals) nasal spray to the reference listed drug in the treatment of seasonal allergic rhinitis. Additionally both the test and the reference formulations were tested for superiority against a placebo nasal spray.
Interventions
- DRUG Placebo
- DRUG Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals)
- DRUG Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 727 participants |
| Start Date | 2010-12-27 |
| Est. Completion | 2011-02-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01279057
The ClinicalTrials.gov registry entry for NCT01279057 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 727 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sandoz, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01279057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01279057 about?
NCT01279057 is a clinical study titled "A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis". This study compared the safety and efficacy of a generic fluticasone furoate (Lek Pharmaceuticals) nasal spray to the reference listed drug in the treatment of seasonal allergic rhinitis. Additionally both the test and the reference formulations were tested for superiority against a placebo nasal sp...
What is the current status of trial NCT01279057?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 727 participants. The study started on 2010-12-27. Estimated completion is 2011-02-08.
What interventions are being tested in trial NCT01279057?
The interventions under investigation include: Placebo (DRUG), Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals) (DRUG), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray (DRUG).
Who is sponsoring clinical trial NCT01279057?
This trial is sponsored by Sandoz, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.